Vimta Labs (VIMTALABS) Stock Overview
Provides contract research and testing services in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for VIMTALABS from our risk checks.
VIMTALABS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeVimta Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹512.20 |
| 52 Week High | ₹902.65 |
| 52 Week Low | ₹376.05 |
| Beta | -0.18 |
| 1 Month Change | 15.46% |
| 3 Month Change | 20.63% |
| 1 Year Change | 8.01% |
| 3 Year Change | 168.55% |
| 5 Year Change | 320.35% |
| Change since IPO | 12.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| VIMTALABS | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 12.0% | 3.4% | 2.1% |
| 1Y | 8.0% | 9.7% | 8.1% |
Return vs Industry: VIMTALABS exceeded the Indian Life Sciences industry which returned 6.8% over the past year.
Return vs Market: VIMTALABS exceeded the Indian Market which returned 6.1% over the past year.
Price Volatility
| VIMTALABS volatility | |
|---|---|
| VIMTALABS Average Weekly Movement | 6.8% |
| Life Sciences Industry Average Movement | 6.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: VIMTALABS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: VIMTALABS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,315 | Harita Vasireddi | vimta.com |
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, and regulators; and a testing laboratory for water, alcoholic, and non-alcoholic beverages.
Vimta Labs Limited Fundamentals Summary
| VIMTALABS fundamental statistics | |
|---|---|
| Market cap | ₹22.89b |
| Earnings (TTM) | ₹775.12m |
| Revenue (TTM) | ₹4.16b |
Is VIMTALABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIMTALABS income statement (TTM) | |
|---|---|
| Revenue | ₹4.16b |
| Cost of Revenue | ₹807.93m |
| Gross Profit | ₹3.35b |
| Other Expenses | ₹2.58b |
| Earnings | ₹775.12m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 17.35 |
| Gross Margin | 80.59% |
| Net Profit Margin | 18.62% |
| Debt/Equity Ratio | 0.7% |
How did VIMTALABS perform over the long term?
See historical performance and comparisonDividends
Does VIMTALABS pay a reliable dividends?
See VIMTALABS dividend history and benchmarks| Vimta Labs dividend dates | |
|---|---|
| Ex Dividend Date | Jun 18 2026 |
| Dividend Pay Date | Jul 08 2026 |
| Days until Ex dividend | 40 days |
| Days until Dividend pay date | 60 days |
Does VIMTALABS pay a reliable dividends?
See VIMTALABS dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/08 07:55 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vimta Labs Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Vijay Madunala | FirstCall Research |